Expert Review of Clinical Immunology is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, dedicated to advancing the field of immunology, with a particular focus on clinical applications and therapeutic developments. With an ISSN of 1744-666X and an E-ISSN of 1744-8409, this journal has made a significant impact in the scientific community, evidenced by its Q2 ranking in both Immunology and Allergy for 2023, as well as solid placements in Scopus ranks (73/233 and 87/236 in their respective categories). Operating from the United Kingdom, the journal publishes comprehensive reviews designed to keep researchers, clinicians, and students updated on cutting-edge advancements and trends in immunology. Although it is not an open-access journal, its high impact factor and rigorous editorial standards reinforce its relevance and importance in providing high-quality, evidence-based information. As we progress towards 2024, Expert Review of Clinical Immunology remains a vital resource for anyone involved in the immunological sciences, facilitating knowledge exchange and fostering innovative research within this critical area of medicine.

The Journal of Dermatology, published by Wiley, is a premier academic journal dedicated to advancing the field of dermatology, with its esteemed reputation reflected in its Q1 ranking in Dermatology and a remarkable Q2 ranking in Miscellaneous Medicine as of 2023. Since its inception in 1974, the journal has become a vital resource for researchers, clinicians, and students alike, covering pioneering studies and cutting-edge advancements in skin health and disease. With a Scopus rank of #32 out of 142 in the Dermatology category, placing it in the 77th percentile, the journal underscores its commitment to fostering knowledge and innovation within the dermatological community. Although the journal operates under a subscription model, it remains an essential platform for disseminating impactful research that shapes clinical practice and enhances patient care. For anyone invested in dermatological sciences, Journal of Dermatology serves as a key publication where critical insights and developments are regularly showcased.

Journal of Drugs in Dermatology, an esteemed publication in the field of dermatology, serves as a vital resource for researchers, clinicians, and healthcare professionals dedicated to advancing knowledge and practices in skin-related therapies and treatments. Established in 2002 and published in the United States, this journal focuses on a wide range of topics pertinent to dermatological pharmacology and therapeutics, reflecting contemporary scientific advancements and innovative approaches to patient care. With a strong presence in Scopus rankings, situating it at rank #73 within the dermatology category, and achieving a commendable Q2 quartile classification in both dermatology and general medicine categories, the journal is committed to enhancing understanding of drug efficacy and safety in dermatological conditions. While the journal maintains a traditional access model, its impact factor underscores its significance in the research community, supporting the ongoing dialogue between academia and clinical practice. We invite professionals and students alike to explore the latest findings and contribute to the progressive discourse on dermatological treatments through this important publication.

The British Journal of Dermatology, published by Oxford University Press, stands as a premier platform for advancing the field of dermatological research and clinical practice since its inception in 1892. With a strong commitment to disseminating high-quality research, this esteemed journal is currently ranked in the Q1 category for both Dermatology and Miscellaneous Medicine in 2023, reflecting its influential position in the academic landscape. As the leading journal in its field, it enjoys a robust Scopus ranking of #1 out of 142 in dermatology, placing it in the 99th percentile globally. The journal covers a wide scope of subjects pertinent to dermatology, including clinical trials, treatment innovations, and epidemiological studies, making it an essential resource for researchers, healthcare professionals, and students alike. Although it is not an open-access publication, it ensures a broad reach through institutional subscriptions, fostering knowledge exchange across the global dermatological community. Based in the heart of the United Kingdom, the British Journal of Dermatology continues to play a crucial role in shaping the future of skin health and disease management.

Australasian Journal of Dermatology is a leading publication in the field of dermatology, issued by Wiley since 1951, and reaching an audience of researchers, clinicians, and students interested in the latest advancements and practices in skin health. With an ISSN of 0004-8380 and an E-ISSN of 1440-0960, this journal stands out with its Q2 ranking in both Dermatology and Miscellaneous Medicine, positioning it within the top 61st percentile of its category according to Scopus. Although it does not provide Open Access options, Australasian Journal of Dermatology is committed to disseminating high-quality research that informs clinical practices and promotes scholarly dialogue. By publishing rigorous and peer-reviewed articles focused on various aspects of dermatological science, the journal plays a pivotal role in enhancing the dermatology community's understanding of skin conditions and treatments, making it an invaluable resource for professionals and students alike.

Psoriasis-Targets and Therapy is a leading open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the knowledge and understanding of psoriasis treatment and management. Launched in 2011, this journal provides a platform for high-quality research that encompasses clinical studies, therapeutic advances, and novel targeted therapies for psoriasis. With a focus on the latest findings and innovative approaches, Psoriasis-Targets and Therapy serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of this dynamic field. The journal's commitment to open-access publishing ensures that critical insights and breakthroughs are readily available to the global medical community, fostering collaboration and progress in psoriasis treatment strategies. Researchers are encouraged to submit their findings to contribute to the growing body of knowledge that will ultimately improve patient care and outcomes.

Dermatologie, published by SPRINGER HEIDELBERG, is a prominent journal dedicated to the advancing field of dermatology. With its ISSN 2731-7005 and E-ISSN 2731-7013, this journal has established itself as a valuable resource for researchers, professionals, and students alike. Originating in Germany, the journal focuses on disseminating innovative research from 2022 to 2024, contributing significantly to the understanding of skin health and disease management. Despite its current ranking within the Q3 category in dermatology and a Scopus rank of #88/142, it provides critical insights and advances in clinical practice, epidemiology, and therapeutic modalities. With an emphasis on open discourse, it seeks to foster collaboration among healthcare professionals and researchers, thereby enhancing the quality and accessibility of dermatological research. Engage with Dermatologie to stay at the forefront of the latest advancements in skin-related health issues.

Current Breast Cancer Reports is a vital academic journal published by Springer that focuses on the latest research and advancements in the field of breast cancer. With its ISSN 1943-4588 and E-ISSN 1943-4596, this journal serves as an essential resource for oncologists, researchers, and healthcare professionals dedicated to improving diagnosis and treatment strategies for breast cancer. Spanning from 2009 to 2024, it provides a platform for high-quality, peer-reviewed articles that encompass a range of topics, including molecular biology, clinical trials, and innovative therapeutic approaches. Although it is currently classified in the Q3 category in Oncology and is positioned in the 29th percentile, the journal remains committed to elevating its academic impact and contributing meaningfully to the ongoing fight against breast cancer. As it seeks to disseminate critical findings and foster collaboration within the scientific community, Current Breast Cancer Reports is poised to be an indispensable tool for anyone keen on advancing the field.

Pain and Therapy is a prestigious, peer-reviewed journal published by SPRINGER INTERNATIONAL PUBLISHING AG that has been a beacon of research in the field of pain management and neurology since its inception in 2012. With an ISSN of 2193-8237 and an E-ISSN of 2193-651X, this open access journal facilitates the dissemination of high-quality research to a global audience. Recognized within the top Q1 quartile for Anesthesiology and Pain Medicine, and the Q2 category for Clinical Neurology, it ranks impressively within the Scopus indexing, positioned at #20/136 in its primary category, demonstrating an 85th percentile standing. The journal's commitment to open access enhances its impact, allowing researchers, clinicians, and students to explore and contribute to critical developments in pain therapy and management. The convergence of cutting-edge research and innovative therapeutic strategies makes Pain and Therapy an essential resource for anyone dedicated to advancing knowledge in this vital field.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.